A new noninvasive test to help measure and monitor mucosal healing status in Crohn’s disease patients has been introduced by Prometheus Laboratories.
The PROMETHEUS Monitr Crohn’s Disease test can be used as an adjunct to endoscopy or by itself between endoscopies; each test report provides a single objective Mucosal Healing Index Score that can be used to assess disease activity. The test provides a unique combination of 13 biomarkers to assess mucosal healing. Clinical studies of the Monitr test have shown high accuracy and concordance rates with endoscopically visualized mucosal disease activity in adult Crohn’s disease patients, regardless of disease location or treatment regimen.
“Our goal is to see patients achieve mucosal healing, or significant improvements in mucosal health,” said Marla Dubinsky, M.D., Chief of Pediatric Gastroenterology and Hepatology and Co-director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at the Icahn School of Medicine, Mount Sinai. “To do that, we really need an objective way to view snapshots of the mucosa without frequent scoping. The more noninvasive biomarkers we can assay to objectively evaluate the mucosa, the better off patients will be.”
Data on the Monitr test will be presented at the American College of Gastroenterology conference in Orlando, FL.
For more information visit Prometheuslabs.com.